Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia

September 3, 2013

Answering important questions about safety, tolerability and efficacy, the Phase 2a study showed positive top-line results when ETC-1002 was added to statin therapy to treat elevated levels of low density lipoprotein cholesterol (LDL-C).
More »

Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer

September 3, 2013

Ms. Hilleman has over two decades experience as CFO of both private and public companies, including taking four companies public. Most recently, Ms. Hilleman has provided independent financial and strategic consulting for biotech and cleantech companies.
More »

IntegenX to Present Significant Advances in Rapid DNA Technology at the 25th World Congress of the International Society of Forensic Genetics (ISFG)

September 2, 2013

As the first rapid DNA technology to complete SWGDAM developmental validation, the RapidHIT System is ready for global commercialization for human identification in forensics, law enforcement, defense, homeland security, and intelligence community.
More »